<DOC>
	<DOCNO>NCT02271659</DOCNO>
	<brief_summary>The aim present phase III study two-folded : 1 ) show superiority external beam radiotherapy combine brachytherapy boost versus exclusive external beam radiotherapy 2 ) evaluate economic impact treatment . The study include 33 cancer centre , inclusion time 2 year follow-up 5 year .</brief_summary>
	<brief_title>Medical Economic Evaluation Intermediate-risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>age 18 80 year ; life expectancy great 10 year ; prostate adenocarcinoma histologically proven ; prostate cancer intermediaterisk base least one three follow criterion : PSA 10 ng/ml 20 ng/ml , and/or Gleason score 7 and/or T2B . Karnofsky performance status ≥ 60 % consequently performance status ECOG 02. patient beneficiary social security system ( order n° 2006477 April 26th 2006 ) ; sign consent form . PSA level &gt; 20 ; Gleason &gt; 7 ; clinical T3A T3B MRI ( simple suspicion/ doubt MRI regard T3A wo n't exclusion criterion ) ; prostate volume &gt; 60 cc ; pelvic lymph nodes involvement dissection imaging ( ADP &gt; 1.5 cm ) ; concurrent hormone therapy ; presence distant metastasis ( M1 ) ; history abdominal pelvic irradiation ; history prostate resection previous 6 month and/or allow implantation marker ; history uncontrolled cancer and/or treat since less 5 year ( except basalcell carcinoma ) ; urinary discomfort IPSS ( International Prostate Symptom Score ) &gt; 15 ( without alphablocking ) ; inflammatory bowel disorder ulcerative colitis Crohn 's disease ; undergo study may interfere present study ; patient legal protection measure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prostate</keyword>
	<keyword>external beam radiotherapy</keyword>
	<keyword>brachytherapy boost</keyword>
	<keyword>economical evaluation</keyword>
</DOC>